47.83
-0.33 (-0.69%)
| Previous Close | 48.16 |
| Open | 47.85 |
| Volume | 347,043 |
| Avg. Volume (3M) | 780,450 |
| Market Cap | 1,228,861,184 |
| Price / Book | 4.75 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -3.23 |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 33.87 |
| Operating Cash Flow (TTM) | -84.02 M |
| Levered Free Cash Flow (TTM) | -53.00 M |
| Return on Assets (TTM) | -19.03% |
| Return on Equity (TTM) | -26.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tourmaline Bio, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 2.0 |
| Average | -1.63 |
|
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.93% |
| % Held by Institutions | 90.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (BMO Capital, 0.36%) | Hold |
| 48.00 (Piper Sandler, 0.36%) | Hold | |
| 48.00 (Truist Securities, 0.36%) | Hold | |
| 48.00 (Guggenheim, 0.36%) | Hold | |
| 48.00 (Chardan Capital, 0.36%) | Hold | |
| 48.00 (HC Wainwright & Co., 0.36%) | Hold | |
| 48.00 (LifeSci Capital, 0.36%) | Hold | |
| 48.00 (Wedbush, 0.36%) | Hold | |
| Median | 48.00 (0.36%) | |
| Low | 47.50 (Jefferies, -0.69%) | Hold |
| Average | 47.94 (0.23%) | |
| Total | 9 Hold | |
| Avg. Price @ Call | 47.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 15 Sep 2025 | 48.00 (0.36%) | Hold | 47.65 |
| Piper Sandler | 11 Sep 2025 | 48.00 (0.36%) | Hold | 47.60 |
| Chardan Capital | 10 Sep 2025 | 48.00 (0.36%) | Hold | 47.60 |
| 14 Aug 2025 | 70.00 (46.35%) | Buy | 22.39 | |
| Guggenheim | 10 Sep 2025 | 48.00 (0.36%) | Hold | 47.60 |
| 14 Aug 2025 | 55.00 (14.99%) | Buy | 22.39 | |
| HC Wainwright & Co. | 10 Sep 2025 | 48.00 (0.36%) | Hold | 47.60 |
| Truist Securities | 10 Sep 2025 | 48.00 (0.36%) | Hold | 47.60 |
| Jefferies | 09 Sep 2025 | 47.50 (-0.69%) | Hold | 47.64 |
| LifeSci Capital | 09 Sep 2025 | 48.00 (0.36%) | Hold | 47.64 |
| Wedbush | 09 Sep 2025 | 48.00 (0.36%) | Hold | 47.64 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |